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Ring-fencing a budget for cancer drugs: is it fair? 
Ring-fencing a budget for cancer drugs: is it fair? For
J Graham, J Cassidy
Ring-fencing is defined as protecting funds for use in a specific area. In the National 
Health Service in the UK, various methods to ring-fence cancer have been 
employed over the years; more recently the Cancer Drugs Fund in England has 
enabled cancer drugs that would not normally be considered cost-effective to be 
provided to patients. This has created variation in provision between England and 
the devolved countries. While some would argue that ring-fencing allows major 
advances to be made in the treatment of a particular condition, others would 
argue that it is intrinsically unfair. In this debate, Graham and Cassidy have written 
an article arguing the affirmative position and Hughes and Duerden were invited 
to respond directly to their arguments. As with all the RCPE's ‘Current 
controversies', the authors have been asked to take a deliberately polarised 
position and so the views they express may be somewhat overstated. 
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We will argue that ring-fencing of funds for cancer is a 
sensible and correct approach. As a preamble (and to 
deflate the argument that all diseases should be treated 
equally), we need to be clear why cancer is different 
from other diseases.  The diagnosis of cancer immediately 
raises the next question ‘how long have I got?’.  This is 
not the response one gets when telling a patient they 
have a myocardial infarction or diabetes – even though 
these diseases also carry a lethal threat. Why is this? In 
part, it stems from how we report the results of cancer 
trials – x year survival, median time to death, etc. These 
statistics exist for other diseases but are rarely if ever 
discussed with patients. We believe that the current way 
we report results of cancer drug studies consistently 
undervalues the worth of these agents. Median survival 
means little or nothing to an individual. In addition, the 
median statistic hides the patients who do very well. So 
we regularly have the discussion ‘is x weeks more 
survival worthwhile?’. A better way of discussing results 
with patients would be to say x% gain nothing, y% gain a 
little and z% gain a lot. Then patients could decide if the 
gamble to be part of z was a worthwhile thing to do. 
This complicates the ‘standard’ methodology of 
describing worth by quality adjusted life years, so-called 
‘QALYs’. This measure is commonly used by funding 
bodies, such as the National Institute for Health and 
Clinical Excellence (NICE), to make funding decisions 
and is defined by them as a measure of a person’s length 
of life weighted by a valuation of their health related 
quality of life. However the whole concept of QALYs is 
fundamentally flawed in any case. As an example, if you 
lose a leg then your quality of life (QoL) will go down. 
But do all one-legged people then have a low QoL for 
the rest of their lives – no. They ‘acclimatise’ and regain 
some or all of the lost QoL with time. These calculations 
also take no account of the savings that can be derived 
from treating a patient – for example reduced hospital 
admissions, reduced requirements for analgesics, anti-
emetics etc.
Unfortunately there is nothing new about our under-
spending on cancer patients. Nearly 15 years ago 
Leonard and colleagues reported in the BMJ that Britain 
was spending 10-fold less than the US and 3.5-fold less 
than the rest of Europe on cancer care and sadly that 
situation has not improved. Despite our best efforts to 
treat our patients in an evidence-based manner and 
within a constrained National Health Service (NHS), our 
patients still do significantly worse than in other 
countries. In a recent study published in The Lancet, 
there was a more than 12% difference in survival rates 
between the lowest performer, the UK, and the highest 
performer, Australia, for patients with colorectal cancer. 
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In the case of lung cancer, there was only an 8.8% five-
year survival for UK patients compared with 18.4% in 
Canada. The differences in survival rates were particularly 
striking for patients of more than 65 years of age and 
this is clearly concerning, given our noticeably aging 
population.1 
There is a common misconception that we would blow 
the whole NHS budget if we spent money on the 
appropriate treatments for our cancer patients but this 
is just not the case. Richards et al found that only 8% of 
the total cancer care budget for a given inpatient was on 
chemotherapy (compared to 13% for laboratory and 
radiological investigations) and yet no one is suggesting 
we stop performing routine investigations on our 
patients.2 It was estimated a few years ago that while 
approximately £170m a year was being spent on anti-
cancer drugs, including a total chemotherapy drug bill of 
only £58m, that by comparison £250m was being spent 
on just one particular brand of proton pump inhibitor.3 
And the really important thing to remember about all of 
this is that spending money does save lives.  According to 
Department of Health figures, we spend approximately 
£80 on cancer per head of population (per year) and 
have an overall five-year survival for men of 36% and 
women of 47%. In Germany, nearly twice as much is 
spent (£143) and this translates into an additional 10% 
five-year survival (45% for men and 55% for women).
So ring-fencing is protective. We would therefore argue 
that it is good sense to protect the cancer budget. It 
should not be diverted or frittered away in less dangerous 
(no matter how common) diseases states. Not many 
other diseases require such intensive and complex 
management involving surgeons, pathologists, 
radiotherapists, etc all working in a team. The argument 
then becomes how big a budget do we need for cancer? 
In the UK we spend more money on anti-diarrhoeal drugs 
than cytotoxics. These are mainly prescribed for self-
limiting episodes – so we would argue ring-fencing should 
also be used to stop money leaking away in such a 
wasteful way. The fence keeps stuff in and other stuff out.
Our colleagues on the other side of the argument will 
attempt to persuade you that cancer should not be 
treated in a different way to any other illness, that all the 
drugs are expensive, that many of them only give 
patients extra weeks or months… that ring-fencing 
simply takes money from one system and puts it into 
another – a system that is less rigorously tested than 
usual with the current drug funding decision makers: 
NICE and the Scottish Medicines Consortium (SMC). 
But the point is that the current system fails patients and 
therefore until we have a better one, we need a fall-back 
for our patients. We are there to serve the patient’s best 
interests always. There are numerous examples where 
drugs with stunning results for patients – real 
breakthroughs in the battle against cancer – have been 
unjustly not approved by our regulatory bodies 
(discussed in more detail below). Of course injustice is 
a relative phenomenon. But I dare say if any of our 
readers were unlucky enough to contract the cancers in 
question they would wish to get the best drugs – in fact, 
we know that from treating medical colleagues.
Cancer is not only a disease of the elderly – increasingly 
we see young patients with solid tumours. The big 
difference between this and the haematological 
malignancies is that the prognosis is extremely poor. For 
many years we have made small steps improving survival 
using changes in the dosing, scheduling and combinations 
of traditional chemotherapies but the real breakthroughs 
have come from the novel targeted agents. 
Response Evaluation Criteria in Solid Tumours (RECIST) 
computerised tomography (CT) is the common method 
of assessing response to treatment. Essentially, index 
lesions are chosen and the sum added up and then 
response is divided into four subgroups: complete 
response, partial response, stable disease and progressive 
disease. However, these agents are often cytostatic (stop 
the cancer growing) rather than tumour shrinking and 
many doctors and patients would argue that long-term 
stable disease is much more meaningful than a tumour 
shrinkage which is then short-lived. Therefore measuring 
responders as only those with tumour shrinkage may no 
longer be appropriate. Instead, physicians are increasingly 
using waterfall plots (which show the change in size of 
each individual tumour rather than splitting them into 
these arbitrary categories) to illustrate the effectiveness 
of novel agents and it is clear from examining these that 
although only a small percentage of patients may make 
the cut-off for a complete or partial response, that a 
huge number benefit from the treatment. 
For other drugs it is their stunning effectiveness that is 
their downfall. In the case of sunitinib, it was not 
approved by NICE for renal cancer in late 2008, despite 
a more than doubling in Progression Free Survival (PFS) 
(11 versus five months) and a six-month (26 versus 20 
months) advantage in overall survival,4 because the 
authors failed to demonstrate a statistically significant 
overall survival advantage… but the reason the overall 
survival advantage was not possible to demonstrate was 
because the experimental drug was so effective that the 
study was unblinded and many of the patients who were 
not randomised to receive it as part of the study were 
allowed to cross over and have it. There is really no way 
around this – as clinicians it would be extremely hard to 
deny a patient an effective treatment simply because it 
was going to muddy our clinical trial endpoint. 
There is no doubt that the system as it stands fails our 
patients. Major reorganisation is planned for the NHS, 
but it is highly doubtful that the proposed reorganisation is 
going to improve things in the short-term. In an ideal world 
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adequate funding would be available so that we could assess 
our patients in a fair and non-postcode determined manner 
and provide the treatment that is needed – but until that 
day comes ring-fencing needs to stay.
Ring-fencing a budget for cancer drugs: is it fair? Against
D Hughes, M Duerden
Decisions concerning the funding of treatments – cancer 
treatments in particular – evoke strong emotions. Negative 
recommendations by the National Institute for Health and 
Clinical Excellence (NICE) are viewed by some as being 
detrimental to patient care, denying patients with real clinical 
needs access to effective therapies. The UK coalition 
Government has seemingly sympathised with this view, 
although endorsing the overall role of NICE, by introducing 
the Cancer Drugs Fund for England in 2010. The purpose of 
the scheme was to ring-fence £200m per annum of existing 
National Health Service (NHS) funds to enable clinicians to 
prescribe treatments that have not been recommended by 
NICE.1 However, concern about the plight of desperate 
patients, alongside the promise of targeted treatment, makes 
it easy to lose sight of the necessity to rigorously appraise 
experimental treatments.2 It is imperative, therefore, to 
ensure that both current and future patients, and also society, 
are provided with safe, effective and cost-effective 
interventions. Alas, the granting of marketing authorisation 
(‘the license’) does not give such a guarantee. 
Decisions made by NICE are based on rigorous assessments 
of the clinical and economic evidence, and negative 
recommendations (made in around 13% of all appraisals) are 
only issued if there is a lack of evidence for clinical 
effectiveness or if the medicine is not considered to be a 
cost-effective use of NHS resources, compared with current 
NHS practice. The Cancer Drugs Fund is therefore used to 
buy treatments that are not deemed by NICE to be clinically 
effective, or cost-effective and seems to undermine the role 
of NICE in its technology appraisal of cancer drugs.1
In our counterpoint, we provide a public health perspective 
to resource allocation, discuss the implications of the English 
Cancer Drugs Fund, and correct some common fallacies 
concerning health economics.
How effective are new medicines for cancer? Among the 
ten new molecular-targeted drugs approved by the Food 
and Drug Administration (FDA) between 2000 and 2010 
for the treatment of metastatic adult solid tumours, none 
are curative though some may extend life, but by no more 
than a median of five months.3 It is important to recognise 
that if one of these drugs extends survival by a median of 
five months, 50% of people receiving that treatment get 
less than this advantage. With costs typically in the order 
of tens of thousands of pounds per patient (for example, 
lenalidomide costs around £30,000 – or about £200 per 
capsule), it is hardly surprising that most exceed the NICE 
cost-effectiveness threshold (representing the marginal 
value of health) of £20,000 to £30,000 per quality-
adjusted life-year (QALY). To enable more drugs to be 
used, Patient Access Schemes were introduced to discount 
the costs of very expensive treatments to the NHS but 
even with these, some drugs exceeded the upper £30,000 
per QALY threshold. Partly for this reason, an adjustment 
was made in 2009 to allow some cancer drugs to be 
provided at an even higher cost-effectiveness threshold 
using the NICE end of life criteria.4 This threshold appears 
in practice to be around £50,000 per QALY. However the 
Cancer Drugs Fund now allows use of drugs in the English 
NHS that exceed even this very high threshold.
The problem with the Cancer Drugs Fund and with 
applying end of life criteria is that they allow drug 
companies to charge what they think the market can bear 
and do little to exert downward pressure on drug pricing 
in the UK. In any case, drug companies are reluctant to set 
lower drug costs as the UK is often used as a ‘reference 
price’ to set prices in other countries. From 2014, a value-
based pricing mechanism will be introduced (and with it 
the Cancer Drugs Fund will end), with the intent of 
enabling new medicines to be priced according to the 
health benefits generated.5 If companies decline to supply 
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a medicine at a price that relates to its value to the NHS, 
it will be their responsibility – not NICE’s – to explain why. 
This may change the current situation where NICE is seen 
as the bad guy and profit-maximising drug companies are 
seen as the innocent victims. The media and patient 
support groups accuse NICE of denying access to 
treatment but few criticise the extreme costs of treatment 
which may give little benefit to many who receive them.
Should cancer be a special case? Perhaps so, but 
fundamentally, this is an empirical question that needs to 
be asked of the general public. The activity of media and 
patient support groups may suggest that society expects 
this preference but this may not be the case. The counter 
view is that there are equally deserving patients with 
other diseases who may not have such vocal advocacy. 
Few would argue that patients with New York Heart 
Association (NYHA) functional class III/IV congestive 
heart failure are in better states of health, or have better 
prognoses than many patients with cancer. Also, there 
are obvious differences among the cancers, in terms of 
life expectancy, and the quality of life patients experience. 
It may be that short gains in survival for some of these 
cancers are at the expense of considerable additional 
suffering. In these instances the additional costs of 
treatment might be better invested in enhancing palliative 
care service.
If the answer is that, overall, cancer should be a special 
case, then a year of life gained in a person with cancer 
should clearly be valued higher than a year of life gained 
in a patient with some other illness. In general, NICE 
takes the view that the QALY, its preferred measure of 
health outcome, should be valued equally, irrespective of 
disease, age, gender or any other characteristic. However 
there are some exceptions. As already stated, concerning 
end of life criteria, NICE values QALYs gained with 
treatments that extend life expectancy in terminal 
diseases higher than other QALYs. In certain other 
instances, it can also place higher value on treatments of 
severe conditions, treatments that are innovative, and 
treatments for children or disadvantaged populations.6 
The NHS consequently pays more for the marginal 
additional health benefits achieved by treatments such as 
lenalidomide (for multiple myeloma), sunitinib (for 
advanced renal cancer), pemetrexed (for malignant 
mesothelioma), imatinib (for chronic myeloid leukaemia), 
and trastuzumab (for advanced breast cancer). As NHS 
resources are finite, for each QALY gained, more than 
one QALY is lost through the displacement of other 
services necessary to fund these treatments – resulting 
in an overall reduction in population health gain.
In the case of cancer treatments not recommended by 
NICE, such as cetuximab for the treatment of squamous 
cell cancer of the head and neck, which was considered to 
be substantially less cost-effective than what is normally 
considered to be an acceptable use of NHS resources,7 
funding from the Cancer Drugs Fund would represent an 
even greater reduction in population health. It seems to us 
wholly inappropriate and inequitable to use scarce 
resources to buy these inefficient treatments in the NHS 
in England at the expense of the health of the NHS 
population as a whole. Furthermore, in order to qualify for 
access to the Cancer Drugs Fund in England, these 
treatments need to have been turned down in the 
Strategic Health Authority area because an exceptional, 
individual case has not been made. 
How do NICE recommendations compare internationally? 
Compared with Canada and Australia, where the clinical 
and cost-effectiveness of treatments is also assessed, NICE 
is generous. It recommended 87% of its appraised medicines, 
compared with 50% and 54%, respectively.8 However, 
focusing only on cancer drugs, and compared with health 
insurance providers in the USA, positive coverage decisions 
were made by NICE in 39% of cases, compared with 100% 
in the USA.9 Of course, not all Americans are covered by 
health insurance (about 17% are not), and all patients are 
subject to substantial co-payments – which can cost 
thousands of dollars each month. Following the 
recommendations of the Richards report on improving 
access to cancer medicines,10 patients may now pay 
privately for ‘top up’ treatments which are not available on 
the NHS if they desire this, and can afford it.
Is it unethical to ration resources in the NHS on the basis 
of cost? Our view is that with finite healthcare budgets, it 
is unethical not to pay attention to costs as well as overall 
need; we all have a duty to make the best use of public 
money and finite resources. A hypothetical example 
looking at overall population need is seen with vaccines. 
Suppose that £1m is available for a vaccination programme 
and two potential vaccines are available: vaccine A is 95% 
effective, and costs £5 per dose, while vaccine B is 99% 
effective but is twice the cost (£10). Individuals might 
reasonably prefer B. However, from a payer’s perspective, 
£1m would buy 200,000 doses of vaccine A and offer 
protection to 190,000 patients. Given the budget available, 
only 100,000 doses of the more effective vaccine B may 
be purchased, to protect 99,000 individuals. Thus, when 
costs are considered, the seemingly most effective 
intervention for the individual is inferior from a population 
perspective as only about half the number of people are 
immunised. The same principle applies to all health 
technologies, procedures, services and interventions, 
cancer treatments included.
Is a health economic appraisal based on the QALYs 
fundamentally flawed? If it is, accepting the need for 
decisions on the availability of new medicines to be 
informed by health economics, the next challenge would 
be to define a common outcome measure for making valid 
comparisons across different treatments and diseases. 
Our view is that the QALY is well suited to the task. For 
example, a drug which improves lung function, and which 
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increases the time without the symptoms of asthma 
cannot be compared directly – on an asthma symptom-
rating scale – with a drug for cancer which might extend 
life expectancy. The advantage of the QALY is that it is a 
measure which combines both quality and quantity of life 
into a single index and enables such comparisons. In 
constructing the QALY, times spent in states of health are 
valued on a scale of 0 to 1 (0 representing death; 1 
representing full health), and summed over an appropriate 
time horizon. Symptomatic asthma, for instance, might be 
valued at 0.8, compared with 0.95 during times without 
symptoms.  A treatment which improves health by 0.15 
for six months (on average) over a lifetime would result 
in a QALY gain of 0.075 (=0.15*6/12). Compare this with 
a treatment for cancer which extends life by two months 
but, because of adverse events, reduces quality of life from 
0.5 to 0.45 during the six months of treatment. The 
associated QALY gain is 0.058 (=0.45*6/12 – 0.5*4/12). 
From a QALY perspective, the treatment for asthma is 
marginally more effective than the treatment for cancer. 
From an economic perspective, the pertinent issue is 
whether these gains in health are greater than the benefits 
forgone from the displacement of other NHS activities 
required to fund them. Economic evaluations consider the 
net cost of treatment and associated tests, procedures 
and management of adverse events, less the savings of 
reduced hospitalisation, GP appointments etc.
A further argument is that the cost per QALY threshold 
is too low at £20,000–£30,000 per QALY relative to 
another standard treatment and that a higher value is 
warranted. This calls for a closer examination of this 
threshold. It is used for decision-making purposes to 
represent the marginal value of a QALY, that is, if all NHS 
interventions and services were ranked from the most 
to the least efficient, the marginal QALY is the value of 
the one ranked lowest. It is not something which can be 
increased or decreased at the discretion of NICE but is 
generally defined by reasonable assessments of value 
over several sets of appraisals over time. There are 
uncertainties in specifying the threshold value, hence the 
adopted range of £20,000 to £30,000 per QALY, but 
even the lower end may be too high when compared 
with actual NHS activities,11,12 which means we are 
enabling treatments to be used in the NHS that are 
inefficient. Thus the effect of the NICE end of life criteria 
and the ring-fencing afforded by the Cancer Drugs Fund 
in England is to further directly detract from provision 
of other areas of care in the NHS: can we afford this in 
the current cold economic climate and within the 
restraints created by a contracting public sector?
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